A history of firsts

Since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our long history of ‘firsts’ include demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations.

Decades of pushing boundaries and raising standards have placed us at the forefront of our industry, and in recent years, we have invested heavily in gathering unprecedented clinical evidence in support of the latest generation of allergy treatments – sublingual allergy immunotherapy (SLIT) tablets.

When complete, our SLIT-tablet range will cover five of the most common respiratory allergies in the world – house dust mite, grass, trees from the birch tree family, ragweed and Japanese cedar – for all relevant age groups. Our tablets for house dust mite, grass, ragweed and Japanese cedar allergies are already available in many markets and we are working hard to complete the range as quickly as possible.

In 2018, we launched a sister brand klarify.me – offering a broad range of pre-screened drug-free products and services to help people manage their allergies. The overall aim is to transform ALK into a broader-based allergy company that reaches many more people who live with allergy and asthma, and which captures a greater share of the global allergy market by offering solutions for everyone touched by allergy through a comprehensive range of products, services and resources.